Related references
Note: Only part of the references are listed.IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
Stephen B. Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2020)
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
Vince B. C. Biemans et al.
JOURNAL OF CROHNS & COLITIS (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre
M Truyens et al.
Journal of Crohns & Colitis (2020)
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
Uri Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
Audrey Bennett et al.
CROHNS & COLITIS 360 (2020)
Efficacy of intravenous ustekinumab re-induction in patients with Crohn's disease with a loss of response
V. Heron et al.
JOURNAL OF CROHNS & COLITIS (2019)
Ustekinumab therapeutic drug monitoring in Crohn's disease patients with loss of response
V. Heron et al.
JOURNAL OF CROHNS & COLITIS (2019)
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx et al.
JOURNAL OF CROHNS & COLITIS (2019)
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry
M. Iborra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Ustekinumab Intravenous Reinduction Therapy Is Effective at Recapturing Response in Patients With Crohn's Disease
Joshua Hudson et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Intravenous ustekinumab reinduction as a Crohn's disease rescue strategy following a secondary non-response
Juan Maria Vazquez Moron et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2019)
Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease
Ashish Srinivasan et al.
JOURNAL OF CROHNS & COLITIS (2018)
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series
Sunhee Park et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Share Paper
